|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Concordance of Genomic Alterations by Next-generation Sequencing (NGS) in Tumor Tissue vs. Cell-free DNA in Stage I-IV Non-small Cell Lung Cancer.
|
31837429 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MSI status was determined for 130 CRC patients (UICC stage I-IV) using immunohistochemistry, PCR based microsatellite stability testing and by applying MSIsensor to exome sequenced tumors and paired germline DNA.
|
31638937 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV CRCs.
|
30448100 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we aimed to identify CD137/CD137L expression in established colon cancer cell lines and primary tumors (UICC stages I-IV) from patients with documented long-term follow-up.
|
31741755 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using 1708 patients, including 1200 stage I-IV colorectal carcinoma cases in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) and 508 stage III colon cancer cases in a National Cancer Institute-sponsored randomised controlled trial of adjuvant therapy (CALGB/Alliance 89803), we evaluated tumour PTGS2 (COX-2) expression status using immunohistochemistry.
|
30826660 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, the authors describe the technical considerations and functional outcomes in patients undergoing transcortical resection of gliomas of the MTL.METHODSPatients with a glioma (WHO grades I-IV) located within the MTL who had undergone the transcortical approach in the period between 1998 and 2016 were identified through the University of California, San Francisco (UCSF) tumor registry and were classified according to tumor location: preuncus, uncus, hippocampus/parahippocampus, and various combinations of the former groups.
|
29676697 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant differences were still observed when stratified for tumor stage (stage I-IV).
|
31380154 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
They exhibit the full range of neuroglial differentiation including developing CNS to gliomas/glioneuronal tumors WHO grades I-IV.
|
30557172 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A total of 20 pairs of surgically removed tumors and healthy (marginal) tissue samples from colorectal cancer patients at clinical stages (CS) I-IV were analyzed.
|
29254294 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We retrospectively reviewed the records of 183 patients who underwent nephrectomy with inferior vena cava tumor thrombectomy (level I-IV) for renal cell carcinoma between 2000 and 2010.
|
29709665 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Mocetinostat is a spectrum-selective inhibitor of class I/IV histone deacetylases (HDACs), a family of proteins implicated in epigenetic silencing of immune regulatory genes in tumor and immune cells.
|
29124315 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using multiplexed quantitative immunofluorescence (QIF), we measured the levels of PD-L1, IDO-1, B7-H4, and different tumor-infiltrating lymphoycte (TIL) subsets in 552 stages I-IV lung carcinomas from two independent populations.
|
27440266 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Glioma is the most prevalent type of tumor in the brain and is comprised of grades I-IV, according to the WHO classification system.
|
28759011 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor type and grade were classified using the World Health Organization classification (WHO I-IV) and confirmed by pathological analysis.
|
28689260 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of the study was to assess the localization of Polysialic acid (polySia) and Neural cell adhesion molecule (NCAM) in grade I-IV astrocytomas by confocal microscopy, and also to clarify and compare their relationship to conventional clinicopathological features in these tumors.
|
25164322 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The study population consisted of 285 stage I-IV colon cancer patients of which a tumor tissue microarray (TMA) was available.
|
24950792 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Network analysis was performed by pair-wise comparison according to the disease states (tumor or normal), smoking states (current smokers or nonsmokers or former smokers), or the disease stage (stages I-IV).
|
22789435 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We selected primary CRCs from 525 patients (stages I-IV) evenly matched for age (<70 and ≥70), gender and tumor location (right, left and rectum), and 81 primary-metastasis pairs.
|
20635392 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among 602 colon cancer patients (stage I-IV) in two prospective cohort studies, cyclin D1 overexpression was detected in 330 (55%) tumors by immunohistochemistry.
|
19549773 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EGFR, IGFBP-2 and HIF-2A gene expression levels were analyzed by quantitative real-time PCR and differed significantly between grades I-IV astrocytic tumors (P < 0.0001, P < 0.0001 and P: 0.0013, respectively) when analyzed by the Kruskal-Wallis test.
|
17285230 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Matched samples of tumor and adjacent nontumorous mucosa samples from 57 patients with completely resected colorectal carcinoma (International Union Against Cancer Stage I-IV) who underwent complete resection (R0) were quantified for hTERT mRNA expression using real-time RT-PCR.
|
12412163 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In 93 patients we analysed tumour CD44v6 expression in prospectively sampled stage I-IV colorectal adenocarcinomas using RT-PCR and Southern blotting.
|
11961731 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Breast cancer cell lines (n = 7), primary breast tumors (n = 25), and blood from normal donors (n = 40) and breast cancer patients [n = 65; American Joint Committee on Cancer (AJCC) stages I-IV] were assessed for four mRNA tumor markers: beta-human chorionic gonadotropin (beta-hCG), oncogene receptor (c-Met), beta 1-->4-N-acetylgalactosaminyl-transferase, and a tumor-associated antigen (MAGE-A3).
|
11751407 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The prospective study consisted of 290 unselected cases of endometrial carcinomas, FIGO stage I-IV where flow cytometry was performed on fresh tumour tissue blocks from hysterectomy specimens.
|
9258954 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunocytochemistry using anti bcl-2- antibody was performed on 107 breast cancer specimens belonging to node-positive patients from the Ludwig Breast Cancer Studies I-IV and the results were correlated with survival, tumour grade, S-phase, oestrogen and progesterone receptor status and c-erb B-2 expression.
|
7915536 |
1994 |